Melbourne, Australia; 6 March 2015: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”) Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”) is pleased to announce that it has raised approximately AUD$18.6 million at a weighted average issue price of AUD$0.0372 per ordinary share by way of securing commitments to invest from professional and sophisticated investors in the United States. This follows on from the announcement earlier today that shareholders approved all resolutions put at today’s Extraordinary General Meeting of members (EGM). GTG is selling the securities directly to the U.S. investors and has retained Maxim Group LLC to act as placement agent for GTG in connection with this offering. The offer is an offer of 499,999,950 fully paid ordinary shares, represented by 3,333,333 American Depositary Shares (ADS). Each ADS represents one hundred and fifty (150) ordinary shares in Genetic Technologies Limited.